When it comes to corporate tax planning, biopharmas as a group aren’t spectacularly sophisticated. (A few exceptions come to mind, most no...

As baseball executives gathered at the Opryland Hotel in Nashville during the week of Dec. 3 for the trade and free agency frenzy known...

Mother Nature, you've been busy this week. The entire East Coast population remains glued to Wunderground or The Weather Channel as i...

2008 is drawing to a close. Today marks the year's final "Deals of the Week" post. As this blogger takes time to reflect on t...

The US Food & Drug Administration's investigation into adverse reactions associated with Baxter's now-recalled heparin products ...

Here’s some news: Baxter is discontinuing an injectable hospital product because of problems with a third-party contractor it relied on to s...

"We at FDA understand how unsettling this whole situation with heparin is." That is how FDA Office of New Drugs Deputy Director Sa...